Kymera Therapeutics Inc (NAS:KYMR)
$ 35.32 -0.69 (-1.92%) Market Cap: 2.17 Bil Enterprise Value: 1.78 Bil PE Ratio: 0 PB Ratio: 3.11 GF Score: 60/100

Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 08:40PM GMT
Release Date Price: $49.81 (+2.60%)
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Hello, everyone, and welcome. My name is Chris Shibutani. I'm a member of Goldman Sachs Biotech Equity Research team. We're thrilled that you can join us for the 42nd Annual Goldman Healthcare Conference. Our second virtual, hopefully, will be live pretty soon. I'm joined by my colleague, hardworking CJ Zopf. CJ, wave to your fans, who does all the smart work. I make sure, as all the clients know and make sure to hire really smart people to address my many shortcomings. But we are super excited to have Kymera Therapeutics join us today for the presentation.

I think the targeted protein degradation space has just become so much more visible, especially to the public equity investors. So we're really going to look forward to diving into understanding some of the setting that you guys are pursuing and understanding specifically about the company.

We're thrilled to have the entire C-suite basically join us here. Nobody is doing any work back in Cambridge since you're here for the next hour, the CEO, Nello

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot